Jinny Chang, MD
Allergy & Immunology · Santa Barbara, CANPI 1336266857
Payments from drug & device makers
Across 602 payments — averaging $22.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Pharming Healthcare, Inc.$1K
- GSK$1K
- AstraZeneca$817
- CSL Behring$807
- Regeneron Healthcare Solutions, Inc.$667
- plus $6K from 25 others
What the payments were for
- Consulting fees$1,51311%
- Food & beverage$12,02588%
- Education$1161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 54 | $2,539 |
| Pharming Healthcare, Inc. | 36 | $1,490 |
| GSK | 104 | $1,488 |
| AstraZeneca | 38 | $817 |
| CSL Behring | 39 | $807 |
| Regeneron Healthcare Solutions, Inc. | 36 | $667 |
| Sanofi | 28 | $654 |
| Boehringer Ingelheim | 30 | $650 |
| Grifols USA, LLC | 37 | $631 |
| Pfizer | 37 | $567 |
| Novartis | 23 | $425 |
| Shire North American Group Inc | 21 | $372 |
| Alk-abello, Inc | 11 | $367 |
| Optinose US, Inc. | 16 | $322 |
| Incyte Corporation | 14 | $291 |
| Amgen(2 entities) | 14 | $290 |
| Genentech USA, Inc. | 11 | $212 |
| Biocryst US Sales Co., LLC | 9 | $199 |
| Octapharma USA, Inc. | 5 | $127 |
| Ionis Pharmaceuticals, Inc. | 4 | $96 |
| Teva Pharmaceuticals USA, Inc. | 5 | $93 |
| Bio Products Laboratory USA, Inc. | 3 | $90 |
| Greer Laboratories, Inc. | 3 | $86 |
| Covis Pharma GmbH | 4 | $74 |
| Kaleo, Inc. | 4 | $70 |
| Hikma Pharmaceuticals USA | 3 | $69 |
| Organon | 8 | $53 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $41 |
| LEO Pharma Inc. | 1 | $27 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Merck | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,654 in reported general payments places this provider in the 75th percentile of 426 allergy & immunology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 65 | $238,275 |
| Spiriva RespimatTiotropium Bromide | 33 | $24,348 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $20,032 |
| Arnuity ElliptaFluticasone Furoate | 30 | $8,540 |
| AlvescoCiclesonide | 18 | $8,493 |
| Fluticasone Propionate HfaFluticasone Propionate | 30 | $6,923 |
| Qvar RedihalerBeclomethasone Dipropionate | 16 | $5,933 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $5,228 |
| Azelastine Hcl | 118 | $3,969 |
| Ipratropium Bromide | 104 | $3,938 |
| Pulmicort FlexhalerBudesonide | 12 | $3,265 |
| Wixela InhubFluticasone Propion/Salmeterol | 27 | $2,791 |
| BreynaBudesonide/Formoterol Fumarate | 15 | $2,663 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $2,587 |
| Epinephrine | 11 | $2,216 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $2,539 | $238,27565 claims |
| GSKBreo Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,488 | $33,79973 claims |
| Boehringer IngelheimSpiriva Respimat | $650 | $24,34833 claims |
| Covis Pharma GmbHAlvesco | $74 | $8,49318 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $93 | $5,93316 claims |
| AstraZenecaPulmicort Flexhaler | $817 | $3,26512 claims |
| Hikma Pharmaceuticals USAEpinephrine | $69 | $2,21611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 426 allergy & immunology providers in California.
Other allergy & immunology in Santa Barbara
- Myron LiebhaberSanta Barbara$366K
- Kenneth KimLong Beach$18.5M
- Purvi MehraSan Diego$6.3M
- Bob GengSan Diego$6M
- Alexander GreinerSan Diego$4.8M
- Tonny TanusBakersfield$4.5M
- Raffi TachdjianSanta Monica$4.2M
- Vinay MehtaLaguna Niguel$3.3M
- Alan GoldsobelSan Jose$3.3M
- Steven WeinsteinHuntington Beach$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.